In Sequence Survey: Illumina Holds Two-Thirds of Sequencing Market, Splits Desktop Share with Ion PGM | GenomeWeb

Illumina currently holds around 66 percent of the total sequencing market, but the company's share of the desktop market is split evenly with Life Technologies' Ion Torrent PGM, according to a recent survey of 150 In Sequence readers.

The survey, conducted in collaboration with investment firm Mizuho Securities, found that Illumina's HiSeq 2000, GA IIx, and MiSeq claim a total of 66 percent of the sequencing market — 42 percent, 10 percent, and 11 percent, respectively.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.